The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, include blood and bone marrow cancers, anemia, hemophilia, blood-clotting disorders, and leukemia.
April 25th 2024
Advances, challenges, and promising innovations emerge.
Translating Progress in BCMA-Directed Therapy for Multiple Myeloma into Advances in Patient Care
1.0 Credit / Hematology, Oncology
View More
Enhancing the Safety of Outpatient CAR T-Cell Administration in Relapsed/Refractory Lymphomas Through Pharmacist-Directed Initiatives
1.0 Credit / Hematology, Oncology
View More
Ushering in a New Era of Targeted Therapies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Focus on New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Optimizing Outcomes for Older Patients With Acute Myeloid Leukemia: A Focus on Alternative Induction Regimens and Maintenance Therapy
1.0 Credit / Hematology, Oncology
View More
Continuing the Conversation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Addressing Operational Challenges and Integrating New and Emerging Antibody-Based Regimens
1.0 Credit / Hematology, Oncology
View More
Treatment Strategies for Chronic Myeloid Leukemia and the Pharmacist’s Impactful Role
1.0 Credit / Hematology, Oncology
View More
Navigating Current and Emerging Treatment Options for Myelofibrosis After Frontline Failure
1.0 Credit / Oncology
View More
Managed Care Considerations on the Evolving Role of Bispecific Antibodies in Hematologic Malignancies
1.5 Credits / Hematology, Oncology
View More
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
Advancing Myelofibrosis Treatment and Management With JAK Inhibitors and Specialty Pharmacist-led Strategies
1.5 Credits / Hematology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Exploring the Advancements in BTK Inhibitor Therapy for Mantle Cell Lymphoma and the Growing Impact of Oncology Pharmacists
1.0 Credit / Hematology, Oncology
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Advances in the Treatment of Myelofibrosis: Updates and Considerations for Managed Care Professionals
1.0 Credit / Hematology, Oncology
View More
Assessing Emerging Therapies and Multidisciplinary Practices in Managing Myelofibrosis
1.5 Credits / Hematology, Oncology
View More
Chronic Myeloid Leukemia: Navigating Drug Resistance and Optimizing Care
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Optimizing Use of Small Molecule Inhibitors in Chronic Lymphocytic Leukemia: Strategies for Safe and Effective Use
1.0 Credits / Hematology, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Management of DOAC-Associated Bleeding With Reversal Agents: A Comprehensive Approach for Health-System Pharmacists
1.0 Credit / Hematology
View More
Pfizer Inc recently announced the FDA has approved Bosulif (bosutinib), an Abl and Src kinase inhibitor, for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy.
Read More
From The American Journal of Managed Care, "On the Horizon for Multiple Myeloma"
July 5th 2012This article-written by Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD-highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials.
Read More
The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce $5 Million Partnership
July 3rd 2012The Leukemia & Lymphoma Society (LLS) and Celator Pharmaceuticals, Inc announced a significant expansion of their partnership to support clinical development of Celator's CPX-351 (cytarabine:daunorubicin) liposome injection for treatment of adults with acute myeloid leukemia (AML).
Read More